ArticleCureus2025
Serotonin Syndrome Without Overdose: Polypharmacy-Induced Toxicity in a Medically Stable Young Adult.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonin activity in the central and peripheral nervous systems that can lead to symptoms such as altered mental status, autonomic instability (e.g., hyperthermia and hypertensive tachycardia), and neuromuscular abnormalities (e.g., clonus and tremor). We present the case of a 29-year-old male healthcare worker with a history of major depressive disorder (MDD), temporal lobe epilepsy, and suspected obsessive-compulsive disorder (OCD) who presented with sudden-onset agitation, confusion, and abnormal limb movements after his third consecutive 12-hour overnight shift. He had been on stable outpatient doses of escitalopram 20 mg and bupropion XL 150 mg daily for over six months, with naltrexone 50 mg added three months earlier for off-label psychiatric use. In the emergency department, he was treated for presumed seizure or psychosis with multiple sedatives and antipsychotics and subsequently intubated. EEG showed no epileptiform activity, and lumbar puncture was unremarkable. Neurologic findings, including hyperreflexia, clonus, and rigidity, along with rapid clinical improvement following cyproheptadine and benzodiazepines, supported a diagnosis of serotonin syndrome. The patient denied overdose or substance use, and toxicology review concluded that polypharmacy with serotonergic and modulating agents was the likely trigger. We present a young adult who developed serotonin syndrome without overdose, likely due to the cumulative serotonergic effect of multiple prescribed medications at therapeutic doses. This case emphasizes the importance of clinical vigilance in patients with neuropsychiatric comorbidities on centrally acting agents, even in the absence of recent medication changes. It illustrates that even therapeutic combinations of serotonergic and modulating agents can precipitate life-threatening toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.